Fri, November 5, 2010
Thu, November 4, 2010
Wed, November 3, 2010
Tue, November 2, 2010
Mon, November 1, 2010
Sat, October 30, 2010
Fri, October 29, 2010
Thu, October 28, 2010
Wed, October 27, 2010
Tue, October 26, 2010
Mon, October 25, 2010
Sun, October 24, 2010
[ Sun, Oct 24th 2010 ] - Market Wire
Alcon Board Elects New Chairman
Sat, October 23, 2010
Fri, October 22, 2010
Thu, October 21, 2010
Wed, October 20, 2010
[ Wed, Oct 20th 2010 ] - Market Wire
STJ, AGAM, BAC, MDT, BSX
Tue, October 19, 2010

Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2011


//health-fitness.news-articles.net/content/2010/ .. l-results-for-second-quarter-of-fiscal-2011.html
Published in Health and Fitness on Thursday, October 28th 2010 at 13:06 GMT by Market Wire   Print publication without navigation


WALTHAM, Mass.--([ BUSINESS WIRE ])--Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m. ET on Thursday, November 4, 2010, to discuss the companya™s financial results for the second quarter of fiscal 2011. Management will review the quarter and provide an update on the company.

The conference call will be webcast on the investor relations section of Alkermesa™ website at [ www.alkermes.com ] or may be accessed by dialing 1-888-517-2470for domestic callers and 1-630- 827-6818for international callers. The conference call ID number is 7262488.

A replay of the conference call will be available from 7:30 p.m. ET on Thursday, November 4, 2010, through 5:00 p.m. ET on Thursday, November 11, 2010, and may be accessed by visiting Alkermesa™ website or by dialing 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The replay access code is 7262488.

About Alkermes

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol and opioid dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.


Publication Contributing Sources